MA40783A - Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population - Google Patents

Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population

Info

Publication number
MA40783A
MA40783A MA040783A MA40783A MA40783A MA 40783 A MA40783 A MA 40783A MA 040783 A MA040783 A MA 040783A MA 40783 A MA40783 A MA 40783A MA 40783 A MA40783 A MA 40783A
Authority
MA
Morocco
Prior art keywords
vaccines containing
hiv vaccines
population episensus
episensus antigens
antigens
Prior art date
Application number
MA040783A
Other languages
English (en)
Inventor
Eric Bruening
Klaus Frueh
Bette T M Korber
Emily Marshall
Louis Picker
James Theiler
Original Assignee
Los Alamos Nat Security Llc
Univ Oregon Health & Science
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Alamos Nat Security Llc, Univ Oregon Health & Science, Vir Biotechnology Inc filed Critical Los Alamos Nat Security Llc
Publication of MA40783A publication Critical patent/MA40783A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA040783A 2014-10-03 2015-10-04 Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population MA40783A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462059506P 2014-10-03 2014-10-03
US201462059497P 2014-10-03 2014-10-03

Publications (1)

Publication Number Publication Date
MA40783A true MA40783A (fr) 2017-08-08

Family

ID=55631703

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040783A MA40783A (fr) 2014-10-03 2015-10-04 Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population

Country Status (16)

Country Link
US (3) US10894078B2 (fr)
EP (1) EP3200878A4 (fr)
JP (3) JP2017531693A (fr)
KR (1) KR102633096B1 (fr)
CN (1) CN108064181A (fr)
AU (2) AU2015327797A1 (fr)
CA (1) CA2963573C (fr)
EA (1) EA201790680A1 (fr)
HK (1) HK1254806A1 (fr)
IL (1) IL251469B2 (fr)
MA (1) MA40783A (fr)
MX (3) MX2017004275A (fr)
SG (1) SG11201702729YA (fr)
UA (1) UA126890C2 (fr)
WO (1) WO2016054654A1 (fr)
ZA (1) ZA202206809B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
WO2017139065A1 (fr) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Vaccination et immunothérapie contre le vih
CA3028982A1 (fr) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Pre-immunisation et immunotherapie du vih
WO2020243485A1 (fr) * 2019-05-29 2020-12-03 Massachusetts Institute Of Technology Compositions immunogènes spécifiques du vih-1 et méthodes d'utilisation
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
CN114729010A (zh) 2019-08-29 2022-07-08 维尔生物科技有限公司 乙型肝炎病毒疫苗
EP4277652A1 (fr) * 2021-01-14 2023-11-22 Gilead Sciences, Inc. Vaccins contre le vih et méthodes d'utilisation
KR20240049807A (ko) 2021-08-31 2024-04-17 비르 바이오테크놀로지, 인코포레이티드 재조합 hcmv 벡터 및 이의 용도
WO2024173143A2 (fr) * 2023-02-13 2024-08-22 Cyw Investment Co., Ltd Vaccins incorporant des peptides d'épitope th/ctl spécifiques du vih pour la prévention et le traitement d'une infection par le vih et du sida chez des patients

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
EP1427826B1 (fr) 2001-09-20 2011-04-20 Glaxo Group Limited Vaccins VIH-RT-nef-Gag à DNA avec codons optimisés
AUPR842501A0 (en) * 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20070054262A1 (en) * 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
BRPI0414443A (pt) 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
AU2011203095A1 (en) 2003-09-17 2011-07-21 Duke University Consensus/Ancestral Immunogens
NZ547042A (en) 2003-10-10 2010-05-28 Powderject Vaccines Inc Method for eliciting a T-cell response
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
AU2006283101B2 (en) 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine
CN105132439A (zh) * 2006-07-28 2015-12-09 宾夕法尼亚大学托管会 改进的疫苗及其使用方法
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
WO2008121282A2 (fr) * 2007-03-30 2008-10-09 Merck & Co., Inc. Séquences d'antigènes largement représentatifs et leur procédé de sélection
SG10201408784SA (en) * 2008-11-18 2015-02-27 Beth Israel Hospital Antiviral vaccines with improved cellular immunogenicity
AU2010305030A1 (en) * 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
WO2011119920A2 (fr) 2010-03-25 2011-09-29 Oregon Health & Science University Glycoprotéines du cmv et vecteurs recombinés
PT2772265T (pt) 2010-05-14 2018-04-20 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes e seus usos
US8557787B2 (en) * 2011-05-13 2013-10-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
EP2620446A1 (fr) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogènes pour la vaccination contre le VIH
ES2718899T3 (es) 2012-03-02 2019-07-05 Us Gov Health & Human Services Método para modificar la jerarquía de inmunodominio de gag del VIH mediante una vacuna de ADN que expresa regiones conservadas
SG10201705880QA (en) 2013-01-07 2017-08-30 Beth Israel Deaconess Medical Ct Inc Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
BR112015021945A8 (pt) * 2013-03-05 2019-12-03 Univ Oregon Health & Science vetores de citomegalovírus humanos ou animais e seus usos
EP3110953A1 (fr) 2014-02-28 2017-01-04 Janssen Vaccines & Prevention B.V. Vecteurs adénoviaux recombinés se répliquant, compositions et procédés pour les utiliser
WO2016011293A1 (fr) 2014-07-16 2016-01-21 Oregon Health & Science University Cytomégalovirus humain comprenant des antigènes exogènes
KR102159626B1 (ko) 2014-09-26 2020-09-25 베쓰 이스라엘 디코니스 메디칼 센터 인크 인간 면역 결핍 바이러스 감염에 대한 방어 면역을 유도하기 위한 방법 및 조성물
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
DK3390430T3 (da) 2015-12-15 2019-11-18 Janssen Vaccines & Prevention Bv Human immundefektvirus-antigener, vektorer, sammensætninger og fremgangsmåder til anvendelse deraf

Also Published As

Publication number Publication date
US20210046175A1 (en) 2021-02-18
BR112017006865A2 (pt) 2017-12-12
MX2017004275A (es) 2018-01-17
JP2023059272A (ja) 2023-04-26
MX2022003663A (es) 2022-04-25
US20210046174A1 (en) 2021-02-18
CN108064181A (zh) 2018-05-22
ZA202206809B (en) 2023-11-29
HK1254806A1 (zh) 2019-07-26
US10894078B2 (en) 2021-01-19
IL251469B1 (en) 2023-01-01
UA126890C2 (uk) 2023-02-22
IL251469A0 (en) 2017-05-29
WO2016054654A1 (fr) 2016-04-07
AU2021218141A1 (en) 2021-09-09
JP2017531693A (ja) 2017-10-26
AU2015327797A1 (en) 2017-05-11
JP7212020B2 (ja) 2023-01-24
MX2022003664A (es) 2022-04-25
JP7441340B2 (ja) 2024-03-06
KR20170122711A (ko) 2017-11-06
KR102633096B1 (ko) 2024-02-02
US11628215B2 (en) 2023-04-18
EP3200878A1 (fr) 2017-08-09
NZ731173A (en) 2024-04-26
US20170319679A1 (en) 2017-11-09
EA201790680A1 (ru) 2017-11-30
CA2963573C (fr) 2024-02-06
CA2963573A1 (fr) 2016-04-07
JP2021035946A (ja) 2021-03-04
SG11201702729YA (en) 2017-04-27
IL251469B2 (en) 2023-05-01
EP3200878A4 (fr) 2018-05-30
US11554168B2 (en) 2023-01-17
AU2021218141B2 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
MA40783A (fr) Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
ZA201701845B (en) Galnac phosphoramidites, nucleic acid conjugates thereof and their use
DK3134131T3 (en) Nucleic acid vaccines
HK1232123A1 (zh) 親水性抗體-藥物偶聯物
IL263624B (en) HIV vaccine formulation
ZA201703313B (en) Pesticide formulations having physical mode of action
ZA201701461B (en) Antibody formulations
BR112016024806A2 (pt) aplicativo de mensagem privada e métodos associados.
IL247159B (en) Components of pcsk9
IL266237A (en) Tolerogenic DNA composition
ZA201608327B (en) Curcumin-peptide conjugates and formulations thereof
GB201615427D0 (en) Francisella glycoconjugate vaccines
ES1114855Y (es) Conjunto de bandeja, de soporte de pantalla y de pantalla
PT3534936T (pt) Vacina de adn tolerogénica
GB201614387D0 (en) Improved vaccines
GB201603029D0 (en) Vaccine
GB201408819D0 (en) Antigen immunogenicity characteristion assay
ES1126005Y (es) Envoltorio paza taza
GB201514002D0 (en) Francisella glycoconjugate vaccines
GB201415526D0 (en) Antibody Formulations
GB201415298D0 (en) Antibody Formulations
AU2014902031A0 (en) Immunogenic vaccines and uses thereof